Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
ENZ.US
id: 730

Enzo Biochem (ENZ) Asset Sale Case

On March 16, 2023, Enzo Biochem, Inc. (NYSE: ENZ) announced that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs).

In 2022, Enzo Biochem initiated a strategic initiative to restructure operations to target business areas and industry sectors representing major growth opportunities.

Investors may have reasons to suspect $ENZ, its Leaders, and its Advisors of failing to act in the best interests of shareholders.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
16 March 2023
Collecting participants…

Enzo Biochem Inc

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company o...

    Ticker
    ENZ.US
    ISIN
    US2941001024
    CIK
    316253
    Sector
    Healthcare
    Industry
    Diagnostics & Research
    Country
    USA
    Address
    81 Executive Blvd., Farmingdale, NY, United States, 11735